Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | BCL2 | P10415 | 2/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851817 | 0.90 | HTR6 (0.48) | HTR6BCHEDRD2PDK2MAPK1 | |
| SCHEMBL3856211 | 0.82 | PLA2G2A (0.43) | HTR6BCHEDRD2ALDH1A1HTR2C | |
| SCHEMBL5245433 | 0.81 | PDK2 (0.42) | HTR6BCHEALDH1A1PDK2L3MBTL1 | |
| SCHEMBL3860637 | 0.78 | HTR6 (0.56) | HTR6ALDH1A1HTR2CSLC6A4MCL1 | |
| SCHEMBL3853380 | 0.78 | HTR6 (0.38) | HTR6ALDH1A1HTR2CSLC6A4MCL1 | |
| SCHEMBL6176739 | 0.76 | HTR6 (0.55) | HTR6BCHE | |
| SCHEMBL18069184 | 0.74 | HTR6 (0.69) | HTR6BCHEDRD2MCL1BCL2 | |
| SCHEMBL3858178 | 0.74 | HTR6 (0.57) | HTR6BCHEDRD2ALDH1A1HTR2C | |
| SCHEMBL15076180 | 0.73 | RBP4 (0.54) | ALDH1A1PDK2 | |
| SCHEMBL26563553 | 0.73 | PDK2 (0.49) | DRD2ALDH1A1PDK2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2007006677-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | RECQL, AR, DHX35 | HTR6 1077/4885BCHE 3272/4885DRD2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.